SCHEMBL6942147

SCHEMBL6942147

Oc1cc(O)nc(Cc2ccc3c(c2)OCO3)n1

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 2/20 0.49
IGFBP3 P17936 1/20 0.48
ALDH1A1 P00352 3/20 0.48
HSD17B10 Q99714 1/20 0.48
CYP3A4 P08684 5/20 0.47
CYP2D6 P10635 1/20 0.47
TAAR1 Q96RJ0 1/20 0.47
LTB4R Q15722 1/20 0.47
CYP1A2 P05177 2/20 0.46
GAA P10253 1/20 0.46
CYP2C19 P33261 1/20 0.46
ADORA1 P30542 1/20 0.46
SLC6A4 P31645 1/20 0.46
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6942293 0.86 ALDH1A1 (0.51) CALM1IGFBP3ALDH1A1HSD17B10CYP3A4
SCHEMBL6945057 0.81 ALDH1A1 (0.46) CALM1IGFBP3ALDH1A1HSD17B10CYP3A4
SCHEMBL6945769 0.81 ALDH1A1 (0.48) ALDH1A1HSD17B10CYP3A4CYP2D6TAAR1
SCHEMBL6942703 0.80 CALM1 (0.49) CALM1ALDH1A1HSD17B10CYP3A4CYP2D6
SCHEMBL109195 0.78 TAAR1 (0.64) ALDH1A1CYP3A4CYP2D6TAAR1CYP1A2
SCHEMBL6937625 0.78 MAPT (0.46) CALM1IGFBP3ALDH1A1HSD17B10CYP3A4
SCHEMBL6945952 0.78 CALM1 (0.47) CALM1IGFBP3ALDH1A1HSD17B10CYP3A4
SCHEMBL61872 0.77 ALDH1A1 (0.45) ALDH1A1HSD17B10CYP3A4CYP2D6TAAR1
SCHEMBL29375993 0.77 ALDH1A1 (0.45) ALDH1A1HSD17B10CYP3A4CYP2D6TAAR1
SCHEMBL6939968 0.77 ALDH1A1 (0.51) ALDH1A1HSD17B10CYP2D6TAAR1LTB4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268471-B1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AG (DE) 2003-10-15 EP disclosed
US-6525051-B2 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2003-02-25 US disclosed
EP-1268471-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2003-01-02 EP disclosed
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2002-01-24 US disclosed
WO-2001072744-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors NOS1, NOS3, NOS2 CALM1 1648/4885IGFBP3 4000/4885ALDH1A1 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.